September 28, 2018 08:15 AM EDT
R&D

On the heels of a glob­al R&D re­or­ga­ni­za­tion, No­vo Nordisk out­lines 250 US job cuts

John Carroll

Editor & Founder

No­vo Nordisk is slash­ing 250 US jobs in an on­go­ing re­or­ga­ni­za­tion of the busi­ness.

Med­Watch re­port­ed that the phar­ma com­pa­ny is whack­ing 100 back …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times